Complementary information from magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model

Nuclear Medicine and Biology

Volumn 38, Issue 6, 2011, Pages 781-793

  Valable, Samuel ^a   Petit, Edwige ^a   Roussel, Simon ^a   Marteau, Léna ^a   Toutain, Jérôme ^a   Divoux, Didier ^a   Sobrio, Franck ^a   Delamare, Jérôme ^a   Barré, Louisa ^a   Bernaudin, Myriam ^a  

^a UNIVERSITÉ DE CAEN   (France)

Author keywords

18F FMISO; Antiangiogenic; Glioma; Hypoxia; MRI; PET

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; FLUORODEOXYGLUCOSE F 18; SUNITINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD VESSEL PERMEABILITY; BRAIN BLOOD VOLUME; BRAIN HYPOXIA; CANCER GROWTH; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TISSUE LEVEL; GLIOMA; IMAGE ANALYSIS; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RAT; SIGNAL DETECTION; TISSUE DISTRIBUTION; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; BIOLOGICAL TRANSPORT; BRAIN; BRAIN NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; GLIOMA; INDOLES; KINETICS; MAGNETIC RESONANCE IMAGING; MISONIDAZOLE; NEOVASCULARIZATION, PATHOLOGIC; PERMEABILITY; POSITRON-EMISSION TOMOGRAPHY; PYRROLES; RATS; TREATMENT OUTCOME;

EID: 80051689853     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.01.010     Document Type: Article

References (43)

1. Busk M., Horsman M.R., Jakobsen S., Hansen K.V., Bussink J., van der Kogel A., et al. Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast?. Radiother Oncol 2009, 92:429-436.
2. 18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res 2008, 14:2623-2630.
3. Rampling R., Cruickshank G., Lewis A.D., Fitzsimmons S.A., Workman P. Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 1994, 29:427-431.
4. Dreyfuss J.M., Johnson M.D., Park P.J. Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers. Mol Cancer 2009, 8:71.
5. Norden A.D., Drappatz J., Wen P.Y. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 2008, 7:1152-1160.
6. Verhoeff J.J.C., van Tellingen O., Claes A., Stalpers L.J.A., van Linde M.E., Richel D.J., et al. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 2009, 9:444.
7. Miletic H., Niclou S.P., Johansson M., Bjerkvig R. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Expert Opin Ther. Targets 2009, 13:455-468.
8. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-844.
9. Rubenstein J.L., Kim J., Ozawa T., Zhang M., Westphal M., Deen D.F., et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000, 2:306-314.
10. Ran S., Huang X., Downes A., Thorpe P.E. Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy. Neoplasia 2003, 5:297-307.
11. Kunkel P., Ulbricht U., Bohlen P., Brockmann M.A., Fillbrandt R., Stavrou D., et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001, 61:6624-6628.
12. de Boüard S., Herlin P., Christensen J.G., Lemoisson E., Gauduchon P., Raymond E., et al. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol 2007, 9:412-423.
13. Sandström M., Johansson M., Andersson U., Bergh A., Bergenheim A.T., Henriksson R. The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model. Br J Cancer 2004, 91:1174-1180.
14. Goldbrunner R.H., Bendszus M., Wood J., Kiderlen M., Sasaki M., Tonn J. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery 2004, 55:426-432. discussion 432.
15. Rahman R., Smith S., Rahman C., Grundy R. Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma. J Oncol 2010, 251231.
16. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7:987-989.
17. Amberger-Murphy V. Hypoxia helps glioma to fight therapy. Curr Cancer Drug Targets 2009, 9:381-390.
18. Cosse J., Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem 2008, 8:790-797.
19. Brizel D.M., Sibley G.S., Prosnitz L.R., Scher R.L., Dewhirst M.W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997, 38:285-289.
20. Martinive P., Defresne F., Bouzin C., Saliez J., Lair F., Grégoire V., et al. Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res 2006, 66:11736-11744.
21. Gatenby R.A., Kessler H.B., Rosenblum J.S., Coia L.R., Moldofsky P.J., Hartz W.H., et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1988, 14:831-838.
22. Padhani A.R., Krohn K.A., Lewis J.S., Alber M. Imaging oxygenation of human tumours. Eur Radiol 2007, 17:861-872.
23. Gross M.W., Karbach U., Groebe K., Franko A.J., Mueller-Klieser W. Calibration of misonidazole labeling by simultaneous measurement of oxygen tension and labeling density in multicellular spheroids. Int J Cancer 1995, 61:567-573.
24. Valk P.E., Mathis C.A., Prados M.D., Gilbert J.C., Budinger T.F. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 1992, 33:2133-2137.
25. 18F-fluoromisonidazole and 15O-H2O. J Nucl Med 2004, 45:1851-1859.
26. Yamane T., Kikuchi M., Shinohara S., Senda M. Reduction of [(18)F]fluoromisonidazole uptake after neoadjuvant chemotherapy for head and neck squamous cell carcinoma. Mol Imaging Biol 2010.
27. 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005, 46:253-260.
28. 18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009, 75:101-108.
29. Khan N., Li H., Hou H., Lariviere J.P., Gladstone D.J., Demidenko E., et al. Tissue pO2 of orthotopic 9L and C6 gliomas and tumor-specific response to radiotherapy and hyperoxygenation. Int J Radiat Oncol Biol Phys 2009, 73:878-885.
30. Valable S., Eddi D., Constans J., Guillamo J., Bernaudin M., Roussel S., et al. MRI assessment of hemodynamic effects of an angiopoietin-2 overexpression on a brain tumor model. Neuro Oncol 2009, 11(5):488-502.
31. Valable S., Lemasson B., Farion R., Beaumont M., Segebarth C., Remy C., et al. Assessment of blood volume, vessel size, and the expression of angiogenic factors in two rat glioma models: a longitudinal in vivo and ex vivo study. NMR Biomed 2008, 21:1043-1056.
32. 18F]FMISO). Appl Radiat Isot 2007, 65:682-686.
33. Valable S., Barbier E.L., Bernaudin M., Roussel S., Segebarth C., Petit E., et al. In vivo MRI tracking of exogenous monocytes/macrophages targeting brain tumors in a rat model of glioma. Neuroimage 2008, 40:973-983.
34. Boxerman J.L., Schmainda K.M., Weisskoff R.M. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006, 27:859-867.
35. Jain R.K., di Tomaso E., Duda D.G., Loeffler J.S., Sorensen A.G., Batchelor T.T. Angiogenesis in brain tumours. Nat Rev Neurosci 2007, 8:610-622.
36. Wyss M.T., Honer M., Schubiger P.A., Ametamey S.M. NanoPET imaging of [(18)F]fluoromisonidazole uptake in experimental mouse tumours. Eur J Nucl Med Mol Imaging 2006, 33:311-318.
37. 18F-fluoromisonidazole and positron emission tomography: a pilot study. J Cereb Blood Flow Metab 2007, 27:679-689.
38. Szeto M.D., Chakraborty G., Hadley J., Rockne R., Muzi M., Alvord E.C.J., et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Res 2009, 69(10):4502-4509.
39. 18F-fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med 2009, 50:36-44.
40. Winkler F., Kozin S.V., Tong R.T., Chae S., Booth M.F., Garkavtsev I., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6:553-563.
41. Cho H., Ackerstaff E., Carlin S., Lupu M.E., Wang Y., Rizwan A., et al. Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia. Neoplasia 2009, 11:247-259. 2p following 259.
42. Ansiaux R., Baudelet C., Jordan B.F., Crokart N., Martinive P., DeWever J., et al. Mechanism of reoxygenation after antiangiogenic therapy using SU5416 and its importance for guiding combined antitumor therapy. Cancer Res 2006, 66:9698-9704.
43. Batchelor T.T., Sorensen A.G., di Tomaso E., Zhang W., Duda D.G., Cohen K.S., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.